Focus: CeGaT is a German diagnostic company specializing in genetic sequencing for rare disease identification, operating at a small-to-mid-cap scale with 51-200 employees. Founded in 2009, it serves the precision diagnostics market with a focus on sequencing-based solutions.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
CeGaT is a stable niche-diagnostics player suitable for candidates prioritizing rare disease impact over growth trajectories, but limited hiring and pipeline depth reduce long-term career leverage.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for CeGaT
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from CeGaT's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo